Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). J of Skin [Internet]. 2020 Oct. 27 [cited 2025 Apr. 19];4(6):s84. Available from: https://skin.dermsquared.com/skin/article/view/1117